Matthew J Pingree

Dr. Matthew J Pingree


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2020 in Journal of Bone and Joint Surgery
Verified
Journal Article
Open access
ACAntonia F. Chen
Antonia F. Chen
FKFred Khalouf
Fred Khalouf
KZKeith Zora
Keith Zora
MDMichael DePalma
Michael DePalma
LKLynn Kohan
Lynn Kohan
JLJeffrey Lyman
Jeffrey Lyman
Background: Knee osteoarthritis is a painful and sometimes debilitating disease that often affects patients for years. Current treatments include short-lasting and often repetitive nonsurgical options, followed by surgical intervention for appropriate candidates. Cooled radiofrequency ablation (CRFA) is a minimally invasive procedure for the treatment of pain related to knee osteoarthritis. This trial compared the efficacy and safety of CRFA with those of a single hyaluronic acid (HA) injection. Methods: Two hundred and sixty subjects with knee osteoarthritis pain that was inadequately responsive to prior nonoperative modalities were screened for enrollment in this multicenter, randomized trial. One hundred and eighty-two subjects who met the inclusion criteria underwent diagnostic block injections and those with a minimum of 50% pain relief were randomized to receive either CRFA on 4 genicular nerves or a single HA injection. One hundred and seventy-five subjects were treated (88 with CRFA and 87 with HA). Evaluations for pain (Numeric Rating Scale [NRS]), function (Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC]), quality of life (Global Perceived Effect [GPE] score and EuroQol-5 Dimensions-5 Level [EQ-5D-5L] questionnaire), and safety were performed at 1, 3, and 6 months after treatment. Results: Demographic characteristics did not differ significantly between the 2 study groups. A total of 158 subjects (76 in the CRFA group and 82 in the HA group) completed the 6-month post-treatment follow-up. In the CRFA group, 71% of the subjects had ≥50% reduction in the NRS pain score (primary end point) compared with 38% in the HA group (p < 0.0001). At 6 months, the mean NRS score reduction was 4.1 ± 2.2 for the CRFA group compared with 2.5 ± 2.5 for the HA group (p < 0.0001). The mean WOMAC score improvement at 6 months from baseline was 48.2% in the CRFA group and 22.6% in the HA group (p < 0.0001). At 6 months, 72% of the subjects in the CRFA group reported improvement in the GPE score compared with 40% in the HA group (p < 0.0001). Conclusions: CRFA-treated subjects demonstrated a significant improvement in pain relief and overall function compared with subjects treated with a single injection of HA. No serious adverse events related to either procedure were noted, and the overall adverse-event profiles were similar. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

3 January 2020 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
LWLindsay Warner
Lindsay Warner
ABAnna Branstad
Anna Branstad
LGLindsay Hunter Guevara
Lindsay Hunter Guevara
LBLaura Matzke Bitterman
Laura Matzke Bitterman
MPMatthew J Pingree
Matthew J Pingree
JEJason Eldrige
Jason Eldrige
Background: Sufentanil is a potent opioid uncommonly used to manage pain and is rarely administered via an intrathecal pain pump system. Case presentation: This case illustrates the use of intrathecal sufentanil in a 50-year-old Caucasian man for the management of chronic pain; however, the intrathecal drug delivery system experienced a malfunction which led to 1/100th output of the correct dosage. Interesting aspects of this case report include the uncommon choice of sufentanil use for an intrathecal drug delivery system, as well as the unusual pharmacokinetics of this drug. Specifically, this patient did not experience the major withdrawal that would be expected given significant under dosing of opioid, and this may be explained by the lipophilicity and context-sensitive half-times of sufentanil. Conclusions: Because of the absence of a clinically significant withdrawal in this case report, clinicians must be aware of relevant pharmacokinetic properties and unusual intrathecal drug delivery system technologies that influence a patient’s response when device malfunction occurs.

5 May 2022 in Pain Management
Verified
Journal Article
Open access
MPMatthew J Pingree
Matthew J Pingree
MHMark Fb Hurdle
Mark Fb Hurdle
DSDavid A Spinner
David A Spinner
AVAli Valimahomed
Ali Valimahomed
NCNathan D Crosby
Nathan D Crosby
JBJoseph W Boggs
Joseph W Boggs
Objective: This study presents real-world data from a cross-sectional follow-up survey of patients who previously received 60-day peripheral nerve stimulation (PNS) treatment for pain. Materials & ... Plain language summary This study presents the findings from a survey that was sent to patients who previously received a 60-day peripheral nerve stimulation (PNS) treatment for their chronic pain....

30 December 2004 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
MPMatthew J Pingree
Matthew J Pingree
EBE. Peter Bosch
E. Peter Bosch
PLPatrick Liu
Patrick Liu
BSBenn E. Smith
Benn E. Smith

5 January 2021 in Pain
Verified
Journal Article
Closed access
SMSusan M. Moeschler
Susan M. Moeschler
EPE. Morgan Pollard
E. Morgan Pollard
MPMatthew J Pingree
Matthew J Pingree
TPThomas P. Pittelkow
Thomas P. Pittelkow
MBMark A. Bendel
Mark A. Bendel
WHW. Michael Hooten
W. Michael Hooten
The primary aim of this randomized clinical trial is to investigate the effects of ultrasound-guided transversus abdominis plane (TAP) vs ultrasound-guided trigger point injections (TPIs) on numerical rating scale pain scores at month 3 follow-up in patients with a chronic abdominal wall pain. The primary outcome measure was the difference in mean numeric rating scale pain scores between the TAP and TPI groups at month 3 in an intent-to-treat (ITT) analysis. A total of 60 patients were randomized 1:1 to receive an ultrasound-guided TAP block (n = 30) or an ultrasound-guided TPI (n = 30). No significant group differences in baseline demographic or clinical characteristics were observed. The mean baseline pain score for the TAP and TPI groups was 5.5 and 4.7, respectively. In the ITT analysis at month 3, the between-group difference in pain scores was 1.7 (95% confidence interval, 0.3-3.0) favoring the TPI group. In a secondary per-protocol analysis, the between-group difference in pain scores was 1.8 (95% confidence interval, 0.4-3.2) favoring the TPI group. For the ITT and per-protocol analyses, the group differences in pain scores were consistent with a medium effect size. The main finding of this randomized clinical trial is that adults with chronic abdominal wall pain who received a TPI reported significantly lower pain scores at month 3 follow-up compared with patients who received a TAP block.

1 December 2013 in Journal of Ultrasound in Medicine
Verified
Journal Article
Open access
PDF file
GDGeorge W. Deimel
George W. Deimel
MHMark F. B. Hurdle
Mark F. B. Hurdle
NMNaveen Murthy
Naveen Murthy
JCJ. Adam Cartwright
J. Adam Cartwright
JSJay Smith
Jay Smith
MPMatthew J Pingree
Matthew J Pingree
Objectives The primary purpose of this study was to describe and validate a novel sonographically guided costotransverse (CTRV) joint injection technique. Methods The bilateral T3–T10 CTRV joints of an unembalmed cadaveric specimen were localized using a 12–3‐MHz linear array transducer. A 22‐gauge, 2.5‐in spinal needle was directed into the CTRV joint using an in‐plane, lateral‐to‐medial approach under direct sonographic guidance. After needle placement, 3‐dimensional computed tomographic (CT) images were obtained to assess the locations of the needle tips. This step was followed by injection of an iodinated contrast agent and repeated CT to assess the contrast flow pattern. An experienced musculoskeletal radiologist reviewed the CT images and assessed the accuracy of the injections (intra‐ or extra‐articular). For intra‐articular injections, a quantitative assessment of the percentage of injectate within the joint was performed. Results A total of 16 sonographically guided CTRV joint injections were completed on a single torso‐pelvis specimen. Using our technique, 11 of 16 sonographically guided CTRV joint injections (68.8%) placed the contrast agent into the target joint. Quantitative analysis of the arthrograms showed 6 of 11 intra‐articular injections (54.5%) with greater than 50% injectate within the joint capsule. Conclusions To our knowledge, this study is the first to determine the feasibility of sonographically guided CTRV joint injections. Overall, 68.8% of injection attempts produced acceptable CTRV joint arthrograms, which compares favorably to a previously reported 76% accuracy rate for fluoroscopically guided CTRV joint injections. Although these injections are technically challenging, the use of sonographic guidance to perform CTRV joint injections is feasible and warrants further investigation to establish its role in the management of patients presenting with thoracic pain syndromes.